ArriVent Lung Cancer Treatment Fails Late-Stage Trial
ArriVent BioPharma announced that its therapy for a specific type of lung cancer did not achieve its primary objective in a late-stage clinical trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.